These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. [Difluoroquinolone lomefloxacin (Maxaquin): its role among fluoroquinolones, possibilities and prospectives]. Padeĭskaia EN Antibiot Khimioter; 1998; 43(10):4-9. PubMed ID: 9825101 [No Abstract] [Full Text] [Related]
43. [Antimicrobial activity and action mechanism of ofloxacin]. Padeĭskaia EN Antibiot Khimioter; 1996; 41(9):13-23. PubMed ID: 9005780 [No Abstract] [Full Text] [Related]
44. A review of clinical trials with fluoroquinolones with an emphasis on new agents. Blondeau JM Expert Opin Investig Drugs; 2000 Feb; 9(2):383-413. PubMed ID: 11060684 [TBL] [Abstract][Full Text] [Related]
45. Quinolone antibacterials. An update of their pharmacology and therapeutic use. von Rosenstiel N; Adam D Drugs; 1994 Jun; 47(6):872-901. PubMed ID: 7521829 [TBL] [Abstract][Full Text] [Related]
46. (Fluorocyclopropyl)quinolones. 2. Synthesis and Stereochemical structure-activity relationships of chiral 7-(7-amino-5-azaspiro[2.4]heptan-5-yl)-1-(2-fluorocyclopropyl)quinolone antibacterial agents. Kimura Y; Atarashi S; Kawakami K; Sato K; Hayakawa I J Med Chem; 1994 Sep; 37(20):3344-52. PubMed ID: 7932562 [TBL] [Abstract][Full Text] [Related]
47. Fluoronaphthyridines and quinolones as antibacterial agents. 2. Synthesis and structure-activity relationships of new 1-tert-butyl 7-substituted derivatives. Bouzard D; Di Cesare P; Essiz M; Jacquet JP; Kiechel JR; Remuzon P; Weber A; Oki T; Masuyoshi M; Kessler RE J Med Chem; 1990 May; 33(5):1344-52. PubMed ID: 2329555 [TBL] [Abstract][Full Text] [Related]
48. NM441: penetration into gynaecological tissues and in vitro activity against clinical isolates from obstetric and gynaecological patients. Mikamo H; Kawazoe K; Izumi K; Ito K; Tamaya T Drugs; 1995; 49 Suppl 2():326-30. PubMed ID: 8549350 [No Abstract] [Full Text] [Related]
49. [Comparative pharmacokinetics of lomefloxacin and other fluoroquinolones]. Iakovlev VP Antibiot Khimioter; 1998; 43(10):46-52. PubMed ID: 9825111 [No Abstract] [Full Text] [Related]
50. The fluorinated quinolones. Kidwai M; Misra P; Kumar R Curr Pharm Des; 1998 Apr; 4(2):101-18. PubMed ID: 10197035 [TBL] [Abstract][Full Text] [Related]
51. Update of lomefloxacin in vitro activity and spectrum. A multicenter trial testing contemporary pathogens following Food and Drug Administration validation guidelines. Lomefloxacin Activity Study Group. Jones RN; Sader HS; Erwin ME Diagn Microbiol Infect Dis; 1994 Oct; 20(2):93-8. PubMed ID: 7867311 [TBL] [Abstract][Full Text] [Related]
56. Pharmacokinetics of enrofloxacin in chicken. Kan CA Br Poult Sci; 1997 Dec; 38(5):614. PubMed ID: 9511011 [No Abstract] [Full Text] [Related]
57. Lomefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Wadworth AN; Goa KL Drugs; 1991 Dec; 42(6):1018-60. PubMed ID: 1724637 [TBL] [Abstract][Full Text] [Related]
58. Quinolinecarboxylic acids. 3. Synthesis and antibacterial evaluation of 2-substituted-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de] [1,4]benzothiazine-6-carboxylic acids related to rufloxacin. Cecchetti V; Fravolini A; Pagella PG; Savino A; Tabarrini O J Med Chem; 1993 Oct; 36(22):3449-54. PubMed ID: 8230136 [TBL] [Abstract][Full Text] [Related]
59. Effect of lomefloxacin on the normal oral and intestinal microflora. Edlund C; Brismar B; Nord CE Eur J Clin Microbiol Infect Dis; 1990 Jan; 9(1):35-9. PubMed ID: 2303064 [TBL] [Abstract][Full Text] [Related]